A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

被引：0
|
作者：
Shan, Yan-Shen
Li, Chung-Pin
Khan, Gazala
Lee, Woo Jin
Choi, Hye Jin
Chang, Heung-Moon
Lee, Moon Hee
Wallmark, John M.
Chen, Pei-Ni
机构：
[1] NCKU & NCKUH, Coll Med, Tainan, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei, Taiwan
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[5] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[7] Inha Univ, Dept Internal Med, Coll Med, Incheon, South Korea
[8] Associates Oncol Hematol PC, Rockville, MD USA
[9] Golden Biotechnol Corp, New Taipei City, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-199-2823; 298-145-222-184-1022-9122; 283-2494; 261-492-2769; 298-145-222-184-1022-9124; 298-145-222-184-1022-8913; 283-237-267; 4; 3; 2; 219; 3618; 176; 12; 6; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.648
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：648 / 648
页数：1
相关论文
共 50 条
  • [41] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [42] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Laheru, Daniel A.
    Smith, Lon S.
    Wood, Tina E.
    Korn, Ronald L.
    Desai, Neil
    Trieu, Vuong
    Iglesias, Jose L.
    Zhang, Hui
    Soon-Shiong, Patrick
    Shi, Tao
    Rajeshkumar, N. V.
    Maitra, Anirban
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554
  • [43] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
    Barrera, Ivan
    Filimon, Sabin Dragos
    Meng, Jassy
    Kavan, Tomas
    Rho, Young Soo
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results
    Carrato, Alfredo
    Maria Vieitez, Jose
    Benavides, Manuel
    Rodriguez-Garrote, Mercedes
    Castillo, Alfredo
    Duran Ogalla, Gema
    Bermejo, Laura Garcia
    Ruiz de Mena, Inmaculada
    Guillen-Ponce, Carmen
    Aranda, Enrique
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 51 - 58
  • [47] Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by folfirinox in metastatic pancreatic adenocarcinoma
    Assenat, E.
    de la Fouchardiere, C.
    Mollevi, C.
    Samalin, E.
    Portales, F.
    Desseigne, F.
    Carenco, C.
    Dupuy, M.
    Lopez-Martinez, E.
    Fiess, C.
    Mazard, T.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [49] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [50] Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer
    Lim, Alexander
    Kim, Dae Won
    Kim, Kunhwa
    Kim, Richard D.
    Bottiglieri, Salvatore Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345